Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
最新股票文章
日元走势预测：第三方价格目标
2025年截至目前，美元兑日元（USD/JPY）汇率年内下跌约9.41%。 2025年4月25日，日元兑美元收于142.8790，创下自2024年9月以来的最强水平之一，较2024年7月的高点161.942下跌约11.77%。
14:34, 19 六月 2025
评分与评论
评分与评论
